# An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria

> **NCT03938272** · PHASE3 · TERMINATED · sponsor: **OxThera** · enrollment: 22 (actual)

## Conditions studied

- Hyperoxaluria, Primary

## Interventions

- **BIOLOGICAL:** Oxabact OC5 - Oxalobacter formigenes Strain HC-1

## Key facts

- **NCT ID:** NCT03938272
- **Lead sponsor:** OxThera
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-14
- **Primary completion:** 2021-07-14
- **Final completion:** 2021-07-14
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Parent, pivotal study (OC5-DB-02) did not meet primary endpoint. No safety concerns for early termination.
- **Last updated:** 2021-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03938272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03938272, "An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03938272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*